NCT02800330View on ClinicalTrials.gov

The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib

PHASE4CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

February 28, 2018

Study Completion Date

February 28, 2018

Conditions
Colorectal NeoplasmsGastrointestinal Stromal Tumors
Interventions
DRUG

Esomeprazole 40mg concomitantly

During phase B the patients will use esomeprazole 40mg concomitantly with regorafenib for 5 days.

DRUG

Esomeprazole 40mg before

During phase C the patients will use esomeprazole 40mg 3 hours before regorafenib for 5 days.

DRUG

Regorafenib 160mg or 120mg

Patients will use regorafenib 160mg or 120mg during all phases (A, B, C)

Trial Locations (1)

3015 CE

Erasmus Medical Center, Rotterdam

Sponsors
All Listed Sponsors
lead

Erasmus Medical Center

OTHER